The House Energy and Commerce Committee today approved three health care bills introduced by Congressman Brett Guthrie (KY-02):
The Safeguarding Therapeutics Act (H.R. 5663), which will give the Food and Drug Administration (FDA) the authority to seize and destroy counterfeit medical devices, including counterfeit COVID-19 tests;
The MODERN Labeling Act (H.R. 5668) which will allow generic drug companies to update their product labels for new drug uses if the brand name drug is no longer on the market. This bill will ensure doctors and patients have the most up-to-date information on certain drugs;
And the National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act (H.R. 4866), which will promote drug manufacturing in the United States.
"As we continue to respond to the ongoing coronavirus pandemic, we must do everything we can to protect Americans and keep our country healthy," said Guthrie. "The Safeguarding Therapeutics Act will ensure counterfeit COVID-19 tests and devices are destroyed and kept out of our supply chain. The National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act will invest in manufacturing drugs within the United States in a quick manner, which is especially important given global pharmaceutical supply chain concerns during the pandemic. In addition, the MODERN Labeling Act will help Americans be better informed on the cutting-edge uses of certain drugs. I was proud to work with my colleagues on these bipartisan, commonsense bills, and I look forward to supporting them on the House floor."